Podcast Episodes
Back to Search338: Chinese biotechs, a WHO departure, and post-JPM thoughts
We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a p…
1 year, 8 months ago
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his v…
1 year, 9 months ago
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study f…
1 year, 9 months ago
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
STAT's FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump's nominee for FDA commissioner. Then, we discuss the result…
1 year, 10 months ago
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Depar…
1 year, 10 months ago
333: An H5N1 bird flu update and talent scarcity in the radiopharma field
You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than…
1 year, 10 months ago
332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?
Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump admin…
1 year, 11 months ago
331: AbbVie’s stumble, Amgen’s tumble and more election fallout
Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspond…
1 year, 11 months ago
330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks
To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA repor…
1 year, 11 months ago
329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story
Adam, Allison, and Elaine get into the Halloween spirit this week, discussing their favorite candies — and Eli Lilly and Pfizer's surprise earnings r…
1 year, 11 months ago